Marco A. Goicochea, Ph.D.
Affiliations: | 2011 | Molecular Microbiology and Immunology | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Immunology, Virology BiologyGoogle:
"Marco Goicochea"Parents
Sign in to add mentorIgor S. Lukashevich | grad student | 2011 | University of Maryland Medical School | |
(Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Zapata JC, Goicochea M, Nadai Y, et al. (2014) Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate. Journal of Virology. 88: 3058-66 |
Goicochea M, Nata T, Gallo R, et al. (2014) HBZ RNA may promote cell survival against clastogenic damages and thereby contributes to the development of leukemic ATL cells Retrovirology. 11: 1-1 |
Zapata JC, Poonia B, Bryant J, et al. (2013) An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virology Journal. 10: 52 |
Goicochea MA, Zapata JC, Bryant J, et al. (2012) Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine. 30: 1445-52 |
Jiang X, Dalebout TJ, Bredenbeek PJ, et al. (2011) Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 29: 1248-57 |
Lukashevich IS, Carrion R, Salvato MS, et al. (2008) Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 26: 5246-54 |
Lukashevich IS, Zapata JC, Goicochea M, et al. (2008) Safety and Efficacy of ML29 Reassortant Lassa Fever Vaccine in Non-Human Primates International Journal of Infectious Diseases. 12 |
Sun L, DeMasi L, Lafferty M, et al. (2006) Retrovirology. 3: S77 |